Abstract：Objective To compare the clinical effect of Azithromycin and Roxithromycin in preventing acute attack of chronic obstructive pulmonary disease.Methods A total of 80 patients with chronic obstructive pulmonary disease admitted to Affiliated Zhongshan Hospital of Dalian University from February 2019 to May 2020 were selected as the research objects,and they were divided into the control group and the observation group according to the random number table method,with 40 cases in each group.The observation group was treated with Roxithromycin,the control group was treated with Azithromycin,both groups were treated for 1 week.The changes of St George′s respiratory question(SGRQ) scores were compared before treatment,3 d after treatment and 1 week after treatment,inflammatory indexes(tumor necrosis factor-α[TNF-α],high-sensitivity C-reactive protein[hs-CRP]),pulmonary function indexes (percentage of forced expiratory volume in first second to forced vital capacity[FEV1%]and forced expiratory volume in one second/forced vital capacity[FEV1/FVC]) before and after treatment and the occurrence of adverse reactions were compared between the two groups.Results After treatment for 3 days and 1 week,the SGRQ scores in both groups were lower than those before treatment,and the SGRQ score of the observation group was lower than that of the control group,the differences were statistically significant (P＜0.05).After treatment,the levels of TNF-α and hs-CRP in both groups were lower than those before treatment,and the levels of TNF-α and hs-CRP in the observation group were lower than those in the control group,the differences were statistically significant (P＜0.05).After treatment,the levels of FEV1% and FEV1/FVC in both groups were higher than those before treatment,and the levels of FEV1% and FEV1/FVC in the observation group were higher than those in the control group,the differences were statistically significant(P＜0.05).The total incidence of gastrointestinal discomfort,rash,bitter mouth and tinnitus in the observation group was lower than that in the control group,the difference was statistically significant (P＜0.05).Conclusion The use of Roxithromycin to prevent the acute attack of chronic obstructive pulmonary disease can effectively improve the clinical symptoms of patients,reduce inflammation,improve lung function,with fewer adverse reactions and high safety.
京公网安备 11010502046607号